See more : MBB SE (0J7X.L) Income Statement Analysis – Financial Results
Complete financial analysis of Sutro Biopharma, Inc. (STRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sutro Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Range Resources Corporation (0KTW.L) Income Statement Analysis – Financial Results
- Kolmar Korea Co., Ltd. (161890.KS) Income Statement Analysis – Financial Results
- Arunjyoti Bio Ventures Limited (ABVL.BO) Income Statement Analysis – Financial Results
- Informa plc (INF.L) Income Statement Analysis – Financial Results
- DIP Corporation (2379.T) Income Statement Analysis – Financial Results
Sutro Biopharma, Inc. (STRO)
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 153.73M | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M | 51.74M | 59.73M |
| Cost of Revenue | 6.82M | 8.29M | 9.77M | 76.96M | 65.61M | 54.26M | 51.90M | 43.55M |
| Gross Profit | 146.92M | 59.48M | 52.11M | -34.24M | -22.88M | -15.84M | -156.00K | 16.18M |
| Gross Profit Ratio | 95.57% | 87.77% | 84.21% | -80.14% | -53.53% | -41.24% | -0.30% | 27.09% |
| Research & Development | 180.43M | 137.17M | 104.40M | 76.96M | 65.61M | 54.26M | 54.64M | 43.55M |
| General & Administrative | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.35M | 1.91M | -77.00K | 87.00K |
| Operating Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Cost & Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Interest Income | 14.51M | 3.46M | 577.00K | 1.51M | 4.07M | 1.62M | 273.00K | 251.00K |
| Interest Expense | 23.75M | 3.35M | 3.14M | 4.08M | 4.35M | 1.62M | 612.00K | 0.00 |
| Depreciation & Amortization | 6.82M | 8.29M | 9.77M | 4.30M | 4.78M | 4.54M | 4.99M | 5.66M |
| EBITDA | -67.92M | -105.07M | -98.52M | -23.75M | -46.62M | -32.82M | -14.09M | 7.36M |
| EBITDA Ratio | -44.18% | -185.16% | -150.46% | -152.74% | -109.08% | -75.89% | -27.22% | 12.33% |
| Operating Income | -89.28M | -128.94M | -98.52M | -71.06M | -55.47M | -37.22M | -19.27M | 1.36M |
| Operating Income Ratio | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% | 2.28% |
| Total Other Income/Expenses | 677.00K | 12.24M | -7.01M | 38.93M | -276.00K | 1.91M | -416.00K | 338.00K |
| Income Before Tax | -88.60M | -116.70M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.70M |
| Income Before Tax Ratio | -57.63% | -172.20% | -170.55% | -75.20% | -130.44% | -91.93% | -38.05% | 2.85% |
| Income Tax Expense | 18.19M | 2.50M | 3.14M | 4.08M | 8.68M | 3.53M | 535.00K | 87.00K |
| Net Income | -106.79M | -119.20M | -108.68M | -36.21M | -55.74M | -35.32M | -19.69M | 1.70M |
| Net Income Ratio | -69.47% | -175.89% | -175.62% | -84.75% | -130.44% | -91.93% | -38.05% | 2.85% |
| EPS | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| EPS Diluted | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| Weighted Avg Shares Out | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
| Weighted Avg Shares Out (Dil) | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
Source: https://incomestatements.info
Category: Stock Reports